# **Anticonvulsant Screening Program**

# Test 76 Results - In-vitro Hippocampal Slice Culture Neuroprotection Assay (NP)

ASP ID: 145016 A Screen ID: 1

Solvent Code: DMSO Solvent Prep:

Test Date: 05-May-2010

Reference: 450:162,166,173

Summary of NP Assay: NMDA

Test Result: Neuroprotective effect

#### Response

Excitotoxin: NMDA

ASP Compound Conc.(uM)	# of slices	% of Total Propidium Iodide Uptake (mean +/- S.E.M)
0	14	51.8 +/- 3.4
10	6	60.0 +/- 2.8
30	8	36.5 +/- 4.8 ✓
60	8	4.6 +/- 0.2
100	7	6.5 +/- 0.3

Note: box is checked if data is significantly different from excitotoxin treatment alone, p<0.05.

IC50(uM): 36.70 +/- 1.07 S.E. M

Comments:

5/13/2014 7:51:55 AM

### TEST 76: in vitro HIPPOCAMPAL SLICE CULTURE NEUROPROTECTION ASSAY

Compound 1: ADD Number: 145016 Batch: A Date Started: 05-May-2010


Compound 2 : ADD Number: Batch: Date Completed: 21-May-2010

**References:** 450: 162, 166, 173

Excitotoxin: NMDA Insult Duration: 4 Hours Solvent: DMSO

Primary Screen Results: Neuroprotection observed

### **EXPERIMENT IMAGES & WELL DESCRIPTION**



### PRIMARY SCREEN EXPERIMENT DESCRIPTION

The "Primary Screen Experiment" is a qualitative assessment of the ability of a compound to prevent excitotoxic cell death. Organotypic hippocampal slice cultures are treated with N-methyl-D-aspartate (NMDA) or kainic acid (KA) to induce neuronal cell death. Propidium iodide (PI), a membrane-impermeant compound, is included in all wells of the culture plate. Dying cells have compromised cell membranes, thus PI may diffuse into the cell, intercalate with DNA and fluoresce. Thus, the intensity of the PI fluorescence is proportional to the amount of cell death in the individual slices. Hippocampal slice cultures are treated with the excitotoxin alone, or where indicated above, with the excitotoxin and either <u>one or two</u> investigational compounds at the concentrations indicated. If neuroprotection occurs as a consequence of the added compound, slice cultures will have a visibly reduced fluorescent intensity when compared to the slice cultures that have been treated with the excitotoxin alone.

## **Anticonvulsant Screening Program**

# <u>Test 76 Results - In-vitro Hippocampal Slice Culture Neuroprotection Assay (NP)</u>

ASP ID: 145016 A Screen ID: 2

Solvent Code: DMSO Solvent Prep:

Test Date: 05-May-2010

Reference: 450:162,166

Summary of NP Assay: Kainic acid

Test Result: No Neuroprotection

**Comments:** 

5/13/2014 7:51:57 AM

## TEST 76: in vitro HIPPOCAMPAL SLICE CULTURE NEUROPROTECTION ASSAY

Compound 1: ADD Number: 145016 Batch: A Date Started: 05-May-2010


Compound 2: ADD Number: Batch: Date Completed: 14-May-2010

**References:** 450: 162, 166

Excitotoxin: Kainic Acid Insult Duration: 4 Hours Solvent: DMSO

Primary Screen Results: No neuroprotection observed

### **EXPERIMENT IMAGES & WELL DESCRIPTION**



### PRIMARY SCREEN EXPERIMENT DESCRIPTION

The "Primary Screen Experiment" is a qualitative assessment of the ability of a compound to prevent excitotoxic cell death. Organotypic hippocampal slice cultures are treated with N-methyl-D-aspartate (NMDA) or kainic acid (KA) to induce neuronal cell death. Propidium iodide (PI), a membrane-impermeant compound, is included in all wells of the culture plate. Dying cells have compromised cell membranes, thus PI may diffuse into the cell, intercalate with DNA and fluoresce. Thus, the intensity of the PI fluorescence is proportional to the amount of cell death in the individual slices. Hippocampal slice cultures are treated with the excitotoxin alone, or where indicated above, with the excitotoxin and either <u>one or two</u> investigational compounds at the concentrations indicated. If neuroprotection occurs as a consequence of the added compound, slice cultures will have a visibly reduced fluorescent intensity when compared to the slice cultures that have been treated with the excitotoxin alone.